Skip to main content

Advertisement

SpringerLink
Log in

Recent Developments in Pediatric Community-Acquired Pneumonia

  • Respiratory Infections (F Arnold, Section Editor)
  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Community-acquired pneumonia (CAP) is the most common acute infectious cause of death in children worldwide. Consequently, research into the epidemiology, diagnosis, treatment, and prevention of pediatric CAP spans the translational research spectrum. Herein, we aim to review the most significant findings reported by investigators focused on pediatric CAP research that has been reported in 2014 and 2015. Our review focuses on several key areas relevant to the clinical management of CAP. First, we will review recent advances in the understanding of CAP epidemiology worldwide, including the role of vaccination in the prevention of pediatric CAP. We also report on the expanding role of existing and emerging diagnostic technologies in CAP classification and management, as well as advances in optimizing antimicrobial use. Finally, we will review CAP management from the policy and future endeavors standpoint, including the influence of clinical practice guidelines on clinician management and patient outcomes, and future potential research directions that are in the early stages of investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. World Health Organization. Pneumonia. Fact sheet No. 331. 2014.

  2. Lee GE et al. National hospitalization trends for pediatric pneumonia and associated complications. Pediatrics. 2010;126(2):204–13.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Keitel K et al. Observed costs and health care use of children in a prospective cohort study on community-acquired pneumonia in Geneva. Switzerland Swiss Med Wkly. 2014;144:w13925.

    CAS  PubMed  Google Scholar 

  4. Jain S et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015;372(9):835–45. This article reports on the results of the largest epidemiological study of pediatric CAP in children to date. Additionally, the use of multiple pathogen detection methods provides unprecedented insight into causative etiologies for CAP, particularly viral causes.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Cantais A et al. Epidemiology and microbiological investigations of community-acquired pneumonia in children admitted at the emergency department of a university hospital. J Clin Virol. 2014;60(4):402–7.

    Article  PubMed  Google Scholar 

  6. Self WH, et al. Respiratory viral detection in children and adults: comparing asymptomatic controls and patients with community-acquired pneumonia. J Infect Dis. 2015.

  7. Rhedin S et al. Respiratory viruses associated with community-acquired pneumonia in children: matched case-control study. Thorax. 2015;70(9):847–53.

    Article  PubMed  Google Scholar 

  8. Wang M et al. Incidence of viral infection detected by PCR and real-time PCR in childhood community-acquired pneumonia: a meta-analysis. Respirology. 2015;20(3):405–12.

    Article  PubMed  Google Scholar 

  9. Goyet S et al. Etiologies and resistance profiles of bacterial community-acquired pneumonia in Cambodian and neighboring countries’ health care settings: a systematic review (1995 to 2012). PLoS One. 2014;9(3), e89637.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Chen K et al. The aetiology of community associated pneumonia in children in Nanjing, China and aetiological patterns associated with age and season. BMC Public Health. 2015;15:113.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Huong Ple T et al. First report on prevalence and risk factors of severe atypical pneumonia in Vietnamese children aged 1–15 years. BMC Public Health. 2014;14:1304.

    Article  PubMed  Google Scholar 

  12. Medjo B et al. Mycoplasma pneumoniae as a causative agent of community-acquired pneumonia in children: clinical features and laboratory diagnosis. Ital J Pediatr. 2014;40:104.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Ma YJ, et al. Clinical and epidemiological characteristics in children with community-acquired mycoplasma pneumonia in Taiwan: a nationwide surveillance. J Microbiol Immunol Infect. 2014; 632–8.

  14. Sun H et al. Epidemiology and clinical profiles of Mycoplasma pneumoniae infection in hospitalized infants younger than one year. Respir Med. 2015;109(6):751–7.

    Article  PubMed  Google Scholar 

  15. Esposito S et al. Enterovirus D68-associated community-acquired pneumonia in children living in Milan. Italy J Clin Virol. 2015;68:94–6.

    Article  PubMed  Google Scholar 

  16. Imamura T, Oshitani H. Global reemergence of enterovirus D68 as an important pathogen for acute respiratory infections. Rev Med Virol. 2015;25(2):102–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Bragstad K et al. High frequency of enterovirus D68 in children hospitalised with respiratory illness in Norway, autumn 2014. Influenza Other Respir Viruses. 2015;9(2):59–63.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Schuster JE et al. Severe enterovirus 68 respiratory illness in children requiring intensive care management. J Clin Virol. 2015;70:77–82.

    Article  PubMed  Google Scholar 

  19. Deva A et al. Pneumococcal infections at a rural tertiary care hospital: a seven year study on isolation rate, clinical spectrum and antibiogram. J Clin Diagn Res. 2014;8(2):50–2.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Diaz MH et al. Molecular detection and characterization of Mycoplasma pneumoniae among patients hospitalized with community-acquired pneumonia in the United States. Open Forum Infect Dis. 2015;2(3):ofv106.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Meyer Sauteur PM et al. Survey of macrolide-resistant Mycoplasma pneumoniae in children with community-acquired pneumonia in Switzerland. Swiss Med Wkly. 2014;144:w14041.

    PubMed  Google Scholar 

  22. Tregnaghi MW et al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial. PLoS Med. 2014;11(6), e1001657.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Abrao WM et al. Impact of the antipneumococcal conjugate vaccine on the occurrence of infectious respiratory diseases and hospitalization rates in children. Rev Soc Bras Med Trop. 2015;48(1):44–9.

    Article  PubMed  Google Scholar 

  24. Angoulvant F et al. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children. Clin Infect Dis. 2014;58(7):918–24.

    Article  CAS  PubMed  Google Scholar 

  25. Greenberg D et al. Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children <5 years. Vaccine. 2015;33(36):4623–9.

    Article  PubMed  Google Scholar 

  26. Naito S, et al. The impact of heptavalent pneumococcal conjugate vaccine on the incidence of childhood community-acquired pneumonia and bacteriologically confirmed pneumococcal pneumonia in Japan. Epidemiol Infect. 2015; 1–13.

  27. Pirez MC et al. Changes in hospitalizations for pneumonia after universal vaccination with pneumococcal conjugate vaccines 7/13 valent and Haemophilus influenzae type b conjugate vaccine in a pediatric referral hospital in Uruguay. Pediatr Infect Dis J. 2014;33(7):753–9.

    Article  PubMed  Google Scholar 

  28. De Schutter I et al. Pneumococcal aetiology and serotype distribution in paediatric community-acquired pneumonia. PLoS One. 2014;9(2), e89013.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Damm O et al. Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany. Eur J Health Econ. 2015;16(5):471–88. This article provides country-level data regarding the potential benefit of widespread influenza vaccination, including expected numbers of averted cases of viral pneumonia. Such information is important for clinicians, public health officials, and third-party payers to consider in decisions of vaccine administration and policy.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Ahn A, et al. Secondhand smoke exposure and illness severity among children hospitalized with pneumonia. J Pediatr. 2015; 869–74.

  31. Azab SF et al. Impact of the socioeconomic status on the severity and outcome of community-acquired pneumonia among Egyptian children: a cohort study. Infect Dis Poverty. 2014;3:14.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Elemraid MA et al. Risk factors for the development of pleural empyema in children. Pediatr Pulmonol. 2015;50(7):721–6.

    Article  PubMed  Google Scholar 

  33. Greenberg D et al. Increased risk for respiratory syncytial virus-associated, community-acquired alveolar pneumonia in infants born at 31–36 weeks of gestation. Pediatr Infect Dis J. 2014;33(4):381–6.

    Article  PubMed  Google Scholar 

  34. Zidan HE, Elbehedy RM, Azab SF. IL6-174 G/C gene polymorphism and its relation to serum IL6 in Egyptian children with community-acquired pneumonia. Cytokine. 2014;67(2):60–4.

    Article  CAS  PubMed  Google Scholar 

  35. Emery DP et al. The impact of primary care on emergency department presentation and hospital admission with pneumonia: a case-control study of preschool-aged children. NPJ Prim Care Respir Med. 2015;25:14113.

    PubMed  PubMed Central  Google Scholar 

  36. Wilson KM et al. Hospitalization for community-acquired pneumonia in children: effect of an asthma codiagnosis. Hosp Pediatr. 2015;5(8):415–22.

    Article  PubMed  Google Scholar 

  37. Coon ER, Maloney CG, Shen MW. Antibiotic and diagnostic discordance between ED physicians and hospitalists for pediatric respiratory illness. Hosp Pediatr. 2015;5(3):111–8.

    Article  PubMed  Google Scholar 

  38. Lai EM et al. Should all children admitted with community acquired pneumonia have blood cultures taken? Indian J Pediatr. 2015;82(5):439–44.

    Article  PubMed  Google Scholar 

  39. Parikh K, Davis AB, Pavuluri P. Do we need this blood culture? Hosp Pediatr. 2014;4(2):78–84.

    Article  PubMed  Google Scholar 

  40. Iroh Tam PY et al. Blood culture in evaluation of pediatric community-acquired pneumonia: a systematic review and meta-analysis. Hosp Pediatr. 2015;5(6):324–36.

    Article  PubMed  Google Scholar 

  41. McCulloh RJ et al. Evaluating the use of blood cultures in the management of children hospitalized for community-acquired pneumonia. PLoS One. 2015;10(2), e0117462.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Schulert GS, Hain PD, Williams DJ. Utilization of viral molecular diagnostics among children hospitalized with community acquired pneumonia. Hosp Pediatr. 2014;4(6):372–6.

    Article  PubMed  PubMed Central  Google Scholar 

  43. McCulloh RJ et al. Potential utility of multiplex amplification respiratory viral panel testing in the management of acute respiratory infection in children: a retrospective analysis. Journal of the Pediatric Infectious Diseases Society. 2014;3(2):146–53.

    Article  PubMed  Google Scholar 

  44. Pernica JM et al. Real-time polymerase chain reaction for microbiological diagnosis of parapneumonic effusions in Canadian children. Can J Infect Dis Med Microbiol. 2014;25(3):151–4.

    PubMed  PubMed Central  Google Scholar 

  45. Aizawa Y et al. Clinical utility of loop-mediated isothermal amplification for rapid diagnosis of Mycoplasma pneumoniae in children. J Med Microbiol. 2014;63(Pt 2):248–51.

    Article  CAS  PubMed  Google Scholar 

  46. Alcoba G et al. Proadrenomedullin and copeptin in pediatric pneumonia: a prospective diagnostic accuracy study. BMC Infect Dis. 2015;15(1):347.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Elemraid MA et al. Utility of inflammatory markers in predicting the aetiology of pneumonia in children. Diagn Microbiol Infect Dis. 2014;79(4):458–62.

    Article  CAS  PubMed  Google Scholar 

  48. Williams DJ et al. Association of white blood cell count and C-reactive protein with outcomes in children hospitalized for community-acquired pneumonia. Pediatr Infect Dis J. 2015;34(7):792–3.

    Article  PubMed  Google Scholar 

  49. Fonseca TS, et al. Pleural effusion increases serum procalcitonin values in children with community-acquired pneumonia. Pediatr Infect Dis J. 2015; 914–5.

  50. Hoshina T et al. The utility of biomarkers in differentiating bacterial from non-bacterial lower respiratory tract infection in hospitalized children: difference of the diagnostic performance between acute pneumonia and bronchitis. J Infect Chemother. 2014;20(10):616–20.

    Article  CAS  PubMed  Google Scholar 

  51. Wrotek A, Jackowska T, Pawlik K. Soluble urokinase plasminogen activator receptor: an indicator of pneumonia severity in children. Adv Exp Med Biol. 2015;835:1–7.

    Article  CAS  PubMed  Google Scholar 

  52. Wrotek A, Jackowska T, Pawlik K. Sodium and copeptin levels in children with community acquired pneumonia. Adv Exp Med Biol. 2015;835:31–6.

    Article  PubMed  Google Scholar 

  53. Esposito S et al. Performance of lung ultrasonography in children with community-acquired pneumonia. Ital J Pediatr. 2014;40:37.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Urbankowska E., et al. Lung ultrasound in the diagnosis and monitoring of community acquired pneumonia in children. Respir Med. 2015; 1207–12.

  55. Reali F et al. Can lung ultrasound replace chest radiography for the diagnosis of pneumonia in hospitalized children? Respiration. 2014;88(2):112–5.

    Article  PubMed  Google Scholar 

  56. Ho MC et al. Usefulness of lung ultrasound in the diagnosis of community-acquired pneumonia in children. Pediatr Neonatol. 2015;56(1):40–5.

    Article  PubMed  Google Scholar 

  57. Lai SH, Wong KS, Liao SL. Value of lung ultrasonography in the diagnosis and outcome prediction of pediatric community-acquired pneumonia with necrotizing change. PLoS One. 2015;10(6), e0130082.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Bradley JS et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53(7):e25–76.

    Article  PubMed  Google Scholar 

  59. Selby A, Pettit K, Brown N. Narrow-spectrum antibiotics are as effective as broad-spectrum antibiotics in the treatment of community-acquired pneumonia. Arch Dis Child Educ Pract Ed. 2015;100(4):223.

    Article  PubMed  Google Scholar 

  60. Queen MA et al. Comparative effectiveness of empiric antibiotics for community-acquired pneumonia. Pediatrics. 2014;133(1):e23–9. This multicenter, retrospective study found that narrow-spectrum antibiotic use for children hospitalized with CAP resulted in similar outcomes to broad-spectrum antibiotic use. This study provides supporting evidence for the national guideline’s recommendation to use narrow-spectrum antibiotics as first-line therapy for children hospitalized with CAP.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Amarilyo G et al. IV Penicillin G is as effective as IV cefuroxime in treating community-acquired pneumonia in children. Am J Ther. 2014;21(2):81–4.

    Article  PubMed  Google Scholar 

  62. Breuer O et al. Antibiotic treatment for children hospitalized with community-acquired pneumonia after oral therapy. Pediatr Pulmonol. 2015;50(5):495–502.

    Article  PubMed  Google Scholar 

  63. Biondi E et al. Treatment of mycoplasma pneumonia: a systematic review. Pediatrics. 2014;133(6):1081–90.

    Article  PubMed  Google Scholar 

  64. Gardiner SJ, Gavranich JB, Chang AB. Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children. Cochrane Database Syst Rev. 2015;1, CD004875.

    PubMed  Google Scholar 

  65. Ambroggio L, et al. Comparative effectiveness of beta-lactam vs. macrolide monotherapy in children with pneumonia diagnosed in the outpatient setting. Pediatr Infect Dis J. 2015; 839–42.

  66. Leyenaar JK et al. Comparative effectiveness of ceftriaxone in combination with a macrolide compared with ceftriaxone alone for pediatric patients hospitalized with community-acquired pneumonia. Pediatr Infect Dis J. 2014;33(4):387–92.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Zhanel GG et al. Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of phase 3 clinical trial data. J Antimicrob Chemother. 2014;69(10):2835–40.

    Article  CAS  PubMed  Google Scholar 

  68. Adam HJ et al. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997–2006. Int J Antimicrob Agents. 2009;34(1):82–5.

    Article  CAS  PubMed  Google Scholar 

  69. Deshpande A et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother. 2013;68(9):1951–61.

    Article  CAS  PubMed  Google Scholar 

  70. Bradley JS et al. The use of systemic and topical fluoroquinolones. Pediatrics. 2011;128(4):e1034–45.

    Article  PubMed  Google Scholar 

  71. Bradley JS et al. Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin. Pediatrics. 2014;134(1):e146–53.

    Article  PubMed  Google Scholar 

  72. You SY et al. Effects of methylprednisolone pulse therapy on refractory Mycoplasma pneumoniae pneumonia in children. Allergy Asthma Immunol Res. 2014;6(1):22–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Izumikawa K et al. Clinical features, risk factors and treatment of fulminant Mycoplasma pneumoniae pneumonia: a review of the Japanese literature. J Infect Chemother. 2014;20(3):181–5.

    Article  PubMed  Google Scholar 

  74. Lavi E et al. Systemic steroid treatment for severe expanding pneumococcal pneumonia. Case Rep Pediatr. 2015;2015:186302.

    PubMed  PubMed Central  Google Scholar 

  75. Greenberg D et al. Short-course antibiotic treatment for community-acquired alveolar pneumonia in ambulatory children: a double-blind, randomized, placebo-controlled trial. Pediatr Infect Dis J. 2014;33(2):136–42.

    Article  PubMed  Google Scholar 

  76. Lassi ZS et al. Systematic review on antibiotic therapy for pneumonia in children between 2 and 59 months of age. Arch Dis Child. 2014;99(7):687–93.

    Article  PubMed  Google Scholar 

  77. Lassi ZS, Imdad A, Bhutta ZA. Short-course versus long-course intravenous therapy with the same antibiotic for severe community-acquired pneumonia in children aged two months to 59 months. Cochrane Database Syst Rev. 2015;6, CD008032.

    PubMed  Google Scholar 

  78. Leyenaar JK et al. Variation in resource utilization for the management of uncomplicated community-acquired pneumonia across community and children’s hospitals. J Pediatr. 2014;165(3):585–91.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Saleh EA, et al. Guideline-concordant antibiotic prescribing for pediatric outpatients with otitis media, community-acquired pneumonia, and skin and soft tissue infections in a large multispecialty healthcare system. Clin Res Infect Dis. 2015. 2(1).

  80. Salih KE et al. Poor adherence to the world health organization guidelines of treatment of severe pneumonia in children at Khartoum. Sudan BMC Res Notes. 2014;7:531.

    Article  PubMed  Google Scholar 

  81. Elemraid MA et al. Changing clinical practice: management of paediatric community-acquired pneumonia. J Eval Clin Pract. 2014;20(1):94–9.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Thomson J et al. Hospital outcomes associated with guideline-recommended antibiotic therapy for pediatric pneumonia. J Hosp Med. 2015;10(1):13–8.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Agweyu A et al. Prevalence and correlates of treatment failure among Kenyan children hospitalised with severe community-acquired pneumonia: a prospective study of the clinical effectiveness of WHO pneumonia case management guidelines. Trop Med Int Health. 2014;19(11):1310–20.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Ross RK et al. Impact of Infectious Diseases Society of America/Pediatric Infectious Diseases Society Guidelines on treatment of community-acquired pneumonia in hospitalized children. Clin Infect Dis. 2014;58(6):834–8.

    Article  PubMed  Google Scholar 

  85. Williams DJ et al. Antibiotic choice for children hospitalized with pneumonia and adherence to national guidelines. Pediatrics. 2015;136(1):44–52.

    Article  PubMed  Google Scholar 

  86. Murtagh Kurowski E et al. Improvement methodology increases guideline recommended blood cultures in children with pneumonia. Pediatrics. 2015;135(4):e1052–9.

    Article  PubMed  Google Scholar 

  87. Wallihan R, Ramilo O. Community-acquired pneumonia in children: current challenges and future directions. J Infect. 2014;69 Suppl 1:S87–90.

    Article  PubMed  Google Scholar 

  88. Rosati P, et al. Are parents of children hospitalized with severe community-acquired pneumonia more satisfied with care when physicians allow them to share decisions on the antibiotic route? Health Expect. 2014.

  89. Ferrero F et al. Effectiveness and safety of a clinical decision rule for guiding the management of children with pneumonia vaccinated against pneumococcal disease: a controlled clinical trial. Arch Argent Pediatr. 2015;113(5):397–403.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Children’s Mercy Hospital, 2401 Gillham Road, Kansas City, MO, 64108, USA

    Russell J. McCulloh & Karisma Patel

  2. Pediatrics and Internal Medicine, University of Missouri–Kansas City, Kansas City, MO, USA

    Russell J. McCulloh

Authors
  1. Russell J. McCulloh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karisma Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Russell J. McCulloh.

Ethics declarations

Conflict of Interest

Dr. McCulloh reports that their research is funded by a Novice Research Award from the Gerber Foundation and a clinical scholar award from Eva and Kenneth Smith Foundation.

Dr. Patel has no conflicts of interests to declare.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Additional information

This article is part of the Topical Collection on Respiratory Infections

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McCulloh, R.J., Patel, K. Recent Developments in Pediatric Community-Acquired Pneumonia. Curr Infect Dis Rep 18, 14 (2016). https://doi.org/10.1007/s11908-016-0521-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11908-016-0521-1

Keywords

Search

Navigation